| Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. | |
| | |
MedLine Citation:
|
PMID: 20070666 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Liver transplantation (LT) for cirrhotic/Hepatocellular carcinoma (HCC) is associated with reduced survival in patients with poor histological features. Preoperative levels of alphafetoprotein (AFP) could predict negative biological features. AFP progression could be more relevant than static AFP levels in predicting LT outcomes. A total of 252 cirrhotic/HCC patients transplanted between 1985 and 2005 were reviewed. One hundred fifty-three patients were analyzed, 99 excluded (for nonsecreting tumors and/or salvage transplantation). Using receiver operating characteristics analysis for recurrence after LT, 'progression' of AFP was defined by >15 microg/L per month before LT. A total of 127 (83%) were transplanted under and 26 (16%) over this threshold. After 45 months of follow-up (median), 5-year overall survival (OS) and recurrence free-survival (RFS) were 72% and 69%, respectively. Five-year survival in the progression group was lower than the nonprogression group (OS 54% vs. 77%; RFS 47% vs. 74%). Multivariate analysis showed progression of AFP>15 microg/L per month and preoperative nodules>3 were associated with decreased OS. Progression group and age>60 years were associated with decreased RFS. Male gender, progression of AFP and size of tumor>30 mm were associated with satellite nodules and/or vascular invasion. In conclusion, increasing AFP>15 microg/L/month while waiting for LT is the most relevant preoperative prognostic factor for low OS/DFS. AFP progression could be a pathological preoperative marker of tumor aggressiveness. |
| | |
Authors:
|
E Vibert; D Azoulay; E Hoti; S Iacopinelli; D Samuel; C Salloum; A Lemoine; H Bismuth; D Castaing; R Adam |
Related Documents
:
|
10071346 - Liver transplantation for hepatocellular carcinoma in patients without underlying liver... 21981876 - Prophylactic irradiation of intervention sites in malignant pleural mesothelioma. 17868066 - Liver transplantation for hepatocellular carcinoma: validation of the ucsf-expanded cri... 17683486 - Comparison of three current staging systems for hepatocellular carcinoma: japan integra... 21505346 - Impact of nutritional factors on survival in patients with inoperable oesophageal cance... 8416886 - Is reseeding from the primary a plausible cause of node failure? |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons Volume: 10 ISSN: 1600-6143 ISO Abbreviation: Am. J. Transplant. Publication Date: 2010 Jan |
Date Detail:
|
Created Date: 2010-01-14 Completed Date: 2010-03-04 Revised Date: 2010-04-06 |
Medline Journal Info:
|
Nlm Unique ID: 100968638 Medline TA: Am J Transplant Country: United States |
Other Details:
|
Languages: eng Pagination: 129-37 Citation Subset: IM |
Affiliation:
|
AP-HP, H?pital Paul Brousse, Centre H?pato-Biliaire, Inserm, Unite 785, Universit? Paris-Sud, Villejuif, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Carcinoma, Hepatocellular
/
blood*,
complications,
pathology,
surgery* Disease-Free Survival Female Humans Liver Cirrhosis / blood*, complications, surgery* Liver Neoplasms / blood*, complications, pathology, surgery* Liver Transplantation* Male Middle Aged Multivariate Analysis Prognosis Survival Rate Time Factors alpha-Fetoproteins / metabolism* |
| Chemical | |
Reg. No./Substance:
|
0/alpha-Fetoproteins |
| Comments/Corrections | |
Comment In:
|
Am J Transplant. 2010 Jan;10(1):10-1
[PMID:
19951278
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The REFLECT Statement: Methods and Processes of Creating Reporting Guidelines for Randomized Control...
Next Document: Opinion: integration of diagnostic and management perspectives for placenta accreta.